Company Profile

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.

Employees

Sector

Biotechnology & Medical Research

More about the company

26/06/25	Regulus Therapeutics Inc.(NasdaqCM:RGLS) dropped from S&P TMI Index	CI
25/06/25	Novartis AGcompleted the acquisition of Regulus Therapeutics Inc..	CI
25/06/25	Swiss Market Index Retreats; Galderma Shares Rise	MT
25/06/25	Novartis: acquires Regulus Therapeutics
25/06/25	Switzerland's Novartis Wraps Up Purchase of US-based Regulus	MT
25/06/25	Novartis completes acquisition of Regulus Therapeutics	DJ
25/06/25	Regulus Therapeutics Inc. Appoints Eduard Marti as Chief Financial Officer	CI
25/06/25	Regulus Therapeutics Inc. Announces Board and Executive Changes	CI
25/06/25	Novartis: takeover bid for Regulus closed: 74.5% held
25/06/25	Novartis announces expiration of Regulus Therapeutics tender offer	DJ
25/06/25	Regulus Therapeutics Inc.(NasdaqCM:RGLS) dropped from NASDAQ Composite Index	CI
23/06/25	Swiss Stocks Begin Week in the Red; Holcim Shares Plummet	MT
23/06/25	Novartis Nears Acquisition of Regulus Therapeutics	MT

01/05/25	Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6	MT
01/05/25	Oppenheimer Downgrades Regulus Therapeutics to Market Perform From Outperform	MT
30/04/25	Wells Fargo Downgrades Regulus Therapeutics to Equalweight From Overweight, $9 Price Target	MT
27/03/25	Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise	MT
02/08/24	Oppenheimer Initiates Regulus Therapeutics at Outperform With $7 Price Target	MT

08/05/25	Regulus: Q1 Earnings Snapshot	AQ
08/05/25	Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates	PR
04/05/25	REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS	BU
01/05/25	New $1.7b Novartis acquisition to advance novel microRNA inhibitor	AQ
30/04/25	Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG	PR

25/06/25	Novartis clôture le rachat de l'américain Regulus Therapeutics
25/06/25	Novartis schliesst Übernahme von Regulus Therapeutics ab
25/06/25	Novartis : l'acquisition de Regulus Therapeutics est bouclée
25/06/25	Novartis: 74,49% azioni Regulus Therapeutics in suo possesso
25/06/25	Novartis : l'OPA sur Regulus est clôturée, 74,5% détenus

3 years	0.83	8.34
5 years	0.76	8.34
10 years	0.76	405

Regulus Therapeutics Inc. Stock

Stocks

RGLS

US75915K3095

Biotechnology & Medical Research

Latest news: Regulus Therapeutics Inc.

Analysts' recommendations: Regulus Therapeutics Inc.

Press Releases: Regulus Therapeutics Inc.

News in other languages: Regulus Therapeutics Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Regulus Therapeutics Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Manager	Title	Age	Since
John McKenna CEO	Chief Executive Officer	-	-
Eduard Marti DFI	Director of Finance/CFO	-	25/06/2025
Jaime Huertas SEC	Corporate Secretary	-	-

Director	Title	Age	Since
John McKenna BRD	Director/Board Member	-	24/06/2025
Eduard Marti BRD	Director/Board Member	-	25/06/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/25/25 A	Pascale Witz	Issuer sale	Director	677	0.0206%
6/25/25 A	Kathryn Collier	Issuer sale	Director	224,215	0.3423%
6/25/25 A	David Baltimore	Tender	Director	450,144	0.6872%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGULUS THERAPEUTICS INC.	+0.25%	-.--%	-	-	617M
WUXI APPTEC CO., LTD.	+1.52%	-7.16%	+51.66%	+67.41%	65B
LONZA GROUP AG	+1.52%	+7.17%	+10.77%	+77.89%	51.2B
ARGENX SE	+0.30%	+0.19%	+2.53%	+56.14%	51.19B
IQVIA HOLDINGS INC.	-0.38%	+2.31%	+29.98%	+40.71%	43.93B
BEONE MEDICINES AG	+0.30%	+4.43%	+16.99%	+120.94%	41.96B
REVOLUTION MEDICINES, INC.	+2.35%	-4.01%	+236.69%	+497.21%	38.14B
CELLTRION, INC.	+2.16%	+10.36%	+18.92%	+59.70%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.49%	+37.09%	+1.80%	25.2B
GENMAB A/S	+1.60%	+3.97%	+21.34%	+22.33%	22.5B
Average	+0.87%	+0.14%	+47.33%	+104.90%	41.37B
Weighted average by Cap.	+0.97%	+0.04%	+46.03%	+106.36%